Market capitalization | $22.08m |
Enterprise Value | $10.86m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
P/B ratio (TTM) P/B ratio | 1.74 |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-20.31m |
Free Cash Flow (TTM) Free Cash Flow | $-15.38m |
Cash position | $13.10m |
As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.
2 Analysts have issued a Cocrystal Pharma Inc forecast:
2 Analysts have issued a Cocrystal Pharma Inc forecast:
Sep '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | - - |
-
|
|
EBITDA | -22 -22 |
12%
12%
|
EBIT (Operating Income) EBIT | -20 -20 |
2%
2%
|
Net Profit | -19 -19 |
4%
4%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Cocrystal Pharma, Inc. is a biotechnology company, which engages in the discovery and development of novel antiviral therapeutics. It focuses on the preclinical and early clinical stage antiviral compounds for unmet medical needs including influenza, Hepatitis C virus, and norovirus infections. The company was founded on January 2, 2014 and is headquartered in Bothell, WA.
Head office | United States |
CEO | Sam Lee |
Employees | 12 |
Founded | 2008 |
Website | www.cocrystalpharma.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.